Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cysteamine plus standard therapy in hospitalized COVID-19 pneumonia (phase 2, safety and immunological effects)
2022-001819-12Phase 2Active
- Sponsor
- National Institute for Infectious Diseases Lazzaro Spallanzani
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of cysteamine in coronavirus pneumonia and coronavirus disease 2019 (COVID-19), sponsored by National Institute for Infectious Diseases Lazzaro Spallanzani. Primary endpoints: Primary safety endpoint (28 days) and Primary safety endpoint (90 days). Started Jun 2022; status: active.
02
Drugs
cysteamine
03
Conditions
coronavirus pneumoniacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-001819-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001819-12.